Trials / Completed
CompletedNCT01643148
The Tetrad BMI, Leptin, Leptin/Adiponectin (L/A) Ratio and CA-15-3 is a Reliable Biomarker of Breast Cancer
Phase 1. Collect Samples of Breast Biopsy Patients Treated at the Hospital Radiology Service Maternal Perinatal Monica Pretelini
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 88 (actual)
- Sponsor
- Materno-Perinatal Hospital of the State of Mexico · Academic / Other
- Sex
- Female
- Age
- 40 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Objective: Evaluate body mass index (BMI), leptin, Leptin/adiponectin (L/A) ratio and cancer antigen (CA) 15-3 together as reliable biomarkers for breast cancer. Patients: Consecutive patients aged between 40 - 60 years, with breast disease and informed consent. Interventions: Patients' Anthropometric and laboratorial characteristics classified by BMI in the group of cancer and patients with benign breast disease as well as biochemical tests of leptin, adiponectin,CA 15-3, hemoglobin, glucose low-density lipoprotein cholesterol (LDLC), high-density lipoprotein cholesterol (HDLC) levels were obtained as well as a blood sample to analyze CA 15-3 levels with a electrochemiluminescence immunoassay. Hypothesis: Using together leptin, L/A ratio, CA 15-3 and BMI could offer a reliable approach to detect high risk women to develop breast cancer.
Detailed description
Serum levels of leptin, adiponectin and CA 15-3, as well as anthropometric and biochemical parameters were analyzed in 88 female patients attending mammography study. Predictive values of BMI, leptin, L/A ratio and CA 15-3 were determined with 95% confidence interval (CI).
Conditions
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2011-10-01
- Completion
- 2012-07-01
- First posted
- 2012-07-18
- Last updated
- 2012-07-18
Source: ClinicalTrials.gov record NCT01643148. Inclusion in this directory is not an endorsement.